Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 95, Issue 10, Pages 1021-1027Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00109-017-1563-z
Keywords
Microbiome; Therapy; Metabolites; Fecal microbiome transplantation; Postbiotics
Funding
- Boehringer Ingelheim Fonds PhD Fellowship
- Yael and Rami Ungar, Israel
- Leona M. and Harry B. Helmsley Charitable Trust
- Gurwin Family Fund for Scientific Research
- Crown Endowment Fund for Immunological Research
- estate of Jack Gitlitz
- estate of Lydia Hershkovich
- Benoziyo Endowment Fund for the Advancement of Science
- Adelis Foundation
- John L. and Vera Schwartz, Pacific Palisades
- Alan Markovitz, Canada
- Cynthia Adelson, Canada
- CNRS (Centre National de la Recherche Scientifique)
- estate of Samuel and Alwyn J. Weber
- Mr. and Mrs. Donald L. Schwarz and Sherman Oaks
- European Research Council
- German-Israel Binational foundation
- Israel Science Foundation
- Minerva Foundation
- Rising Tide foundation
- Alon Foundation scholar award
Ask authors/readers for more resources
The last decade of research has witnessed a tremendous upsurge in our understanding of the intestinal microbiome and its role in a large range of human diseases, which has incited hopes for a rapid clinical utilization of the new insights for the development of microbiome-based therapies. Nonetheless, only a single microbiome-targeted therapy has so far found its way into clinical routine: fecal microbiota transplantation for patients suffering from recurrent Clostridium difficile infections. Herein, we discuss the currenthopes, advances, challenges, and obstacles for translating basic microbiome research into therapeutic applications for a larger number of diseases and provide an outline of how such clinical applications might emerge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available